Gilead Shares Gain After Launching Phase 3 Studies For Coronavirus Treatment

Gilead Sciences ( GILD ) – Get Report shares extended gains Thursday after the drugmaker said its nascent coronavirus treatment will undergo advance human testing in Asia. Gilead said that around 1,000 patients in the region, suffering from both moderate and severe symptoms of the respiratory focused virus, known […]

Click here to view original web page at